18:17 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

Blocking tumor-associated macrophage SIGLEC15 for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal; melanoma; brain cancer; solid tumors Patient sample, cell culture and mouse studies suggest inhibiting SIGLEC15 expressed on tumor-associated macrophages could help treat colorectal cancer, melanoma, glioblastoma and other solid tumors....
23:01 , Mar 4, 2019 |  BC Extra  |  Preclinical News

NextCure's macrophage-based alternative to T cell checkpoint inhibitors

A study led by NextCure co-founder and PD-1 pioneer Lieping Chen has found that blocking SIGLEC15 could boost antitumor T cell responses in immunosuppressive tumor microenvironments. NextCure Inc. (Beltsville, Md.) is testing anti-SIGLEC15 mAb NC318...
03:55 , Dec 14, 2018 |  BC Innovations  |  Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
19:59 , Nov 16, 2018 |  BioCentury  |  Tools & Techniques

Benchtop manufacturing gets smaller

Publisher’s note: This story originally ran in the Nov. 15, 2018 issue of BioCentury Innovations , a comprehensive source of developments in translational research with knowledgeable perspectives on the key innovations, trends and opportunities in...
15:55 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1...
22:43 , Nov 15, 2018 |  BC Innovations  |  Tools & Techniques

Benchtop manufacturing gets smaller

MIT scientists continue to break new ground in benchtop manufacturing systems for biologics. Published in Nature Biotechnology last month, the latest advance from the institute centered on an automated, closed system capable of producing clinical-grade...
11:33 , Nov 13, 2018 |  BC Extra  |  Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates. PD-1 pioneer Lieping Chen...
17:57 , Nov 9, 2018 |  BC Week In Review  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
21:44 , Nov 5, 2018 |  BC Extra  |  Company News

NextCure, Lilly partner to find new immuno-oncology targets

PD-1 pioneer Lieping Chen's NextCure Inc. (Beltsville, Md.) partnered with Eli Lilly and Co. (NYSE:LLY) to use the biotech's FIND-IO platform to discover immuno-oncology targets. FIND-IO identifies new targets on immune-suppressive macrophages, dendritic cells and...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...